14 results
10-Q
2021 Q1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
12 May 21
Quarterly report
4:26pm
customers are developing are early in their lifecycle. We expect an increase in demand for our GMP-grade nucleic acids to the extent that our customers
424B4
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
9 Apr 21
Prospectus supplement with pricing info
4:02pm
of the cell and gene therapy development lifecycle. For example, our mRNA products are used in drug development to assist in the production of immune
DRS
yjs6hj
25 Mar 21
Draft registration statement
12:00am
10-K
69j awuigojajz0zdr
22 Mar 21
Annual report
4:22pm
424B4
rnmc6x
23 Nov 20
Prospectus supplement with pricing info
4:36pm
S-1
opzygzt
29 Oct 20
IPO registration
5:04pm
DRS/A
6n4un8cldwssct5yv534
23 Oct 20
Draft registration statement (amended)
12:00am
DRS/A
1ytodf46phms4fatnjxn
14 Oct 20
Draft registration statement (amended)
12:00am
DRS
uln4n7r2b6qgd
8 Sep 20
Draft registration statement
12:00am
- Prev
- 1
- Next